Company news

Verrica Pharmaceuticals Inc. news in 2026

Verrica Pharmaceuticals Inc.'s news releases, calls and decks from 2026, newest first.

View company

Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results

November 12, 2026

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London

November 10, 2026

Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026

November 5, 2026

Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility

October 22, 2026

Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences

September 30, 2026

Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences

September 10, 2026

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference

September 8, 2026

Verrica Pharmaceuticals Announces Completion of Enrollment in First Pivotal Phase 3 Trial (COVE-2) Evaluating YCANTH® for the Treatment of Common Warts, with Topline Data Expected Q1 2027

August 27, 2026

Verrica Pharmaceuticals Reports Second Quarter 2026 Financial Results

August 6, 2026

Verrica Pharmaceuticals Closes Credit Facility For Up To $27.5 Million in Non-Dilutive Growth Capital

August 6, 2026

Verrica Pharmaceuticals to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 6, 2026

July 30, 2026

Verrica Pharmaceuticals and Medomie Pharma Enter into Exclusive Distribution, Marketing and Supply Agreement to Commercialize YCANTH® for the Treatment of Molluscum Contagiosum in Israel

July 21, 2026

Verrica Pharmaceuticals Announces First U.S. Patient Dosed in the Second Pivotal Clinical Trial (COVE-3) of its Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

June 21, 2026

Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference

May 28, 2026

Verrica Pharmaceuticals to Participate in the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

May 13, 2026

Verrica Pharmaceuticals Reports First Quarter 2026 Financial Results

May 12, 2026

Verrica Pharmaceuticals Announces Upcoming Presentation of Phase 2 Data Highlighting the Potential Abscopal Effects of VP-315 in the Treatment of Basal Cell Carcinoma at the 2026 Society for Investigative Dermatology (SID) Annual Meeting

May 5, 2026

Verrica Pharmaceuticals to Report First Quarter 2026 Financial Results and Provide a Corporate Update on May 12, 2026

May 5, 2026

Verrica Pharmaceuticals Announces Acceptance of Late-Breaking Abstract Highlighting Potential Abscopal Effect of VP-315 for the Treatment of Basal Cell Carcinoma at the Upcoming 2026 Society for Investigative Dermatology Annual Meeting

April 8, 2026

Verrica Pharmaceuticals to Participate in the 25th Annual Needham Virtual Healthcare Conference

April 6, 2026

Verrica Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

March 10, 2026

Verrica Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results and Provide a Corporate Update on March 11, 2026

March 5, 2026

Verrica Pharmaceuticals to Participate in the TD Cowen 46th Annual Health Care Conference

February 23, 2026

Verrica Pharmaceuticals Appoints Chris Chapman as Chief Commercial Officer

February 12, 2026

Verrica Pharmaceuticals Announces Launch of YCANTH® for the Treatment of Molluscum Contagiosum in Japan by Partner Torii Pharmaceutical

February 9, 2026

Verrica Pharmaceuticals Announces First Patient Dosed in Phase 3 Program Evaluating YCANTH® (VP-102) for the Treatment of Common Warts

January 7, 2026

Calls in 2026

Decks in 2026